Somatic mutagenesis in autoimmunity

References

• Kotzin B. L.. Systemic lupus erythematosus. Cell. 1996; 85:303–306.
   PubMed Web of Science ®Google Scholar
• Theofilopoulos A. N., Dixon F. J.. Murine models of systemic lupus erythematosus. Adv. Immunol.. 1985; 37:269–390.
   PubMed Web of Science ®Google Scholar
• Flesher D. L., Sun X., Behrens T. W., Graham R. R., Criswell L. A.. Recent advances in the genetics of systemic lupus erythematosus. Expert Rev. Clin. Immunol.. 2010; 6:461–479.
   PubMed Web of Science ®Google Scholar
• Goodnow C. C.. Multistep pathogenesis of autoimmune disease. Cell. 2007; 130:25–35.
   PubMed Web of Science ®Google Scholar
• Wardemann H., Yurasov S., Schaefer A., Young J. W., Meffre E., Nussenzweig M. C.. Predominant autoantibody production by early human B cell precursors. Science. 2003; 301:1374–1377.
   PubMed Web of Science ®Google Scholar
• Gay D., Saunders T., Camper S., Weigert M.. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exper. Med.. 1993; 177:999–1008.
   PubMed Web of Science ®Google Scholar
• Yachimovich-Cohen N., Fischel R., Bachar N., Yarkoni Y., Eilat D.. Autoimmune NZB/NZW F1 mice utilize B cell receptor editing for generating high-affinity anti-dsDNA autoantibodies from low-affinity precursors. Euro. J. Immunol.. 2003; 33:2469–2478.
   PubMedGoogle Scholar
• Li Y., Louzoun Y., Weigert M.. Editing anti-DNA B cells by Vlambdax. J. Exper. Med.. 2004; 199:337–346.
   PubMedGoogle Scholar
• Halverson R., Torres R. M., Pelanda R.. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nature Immunol.. 2004; 5:645–650.
   PubMed Web of Science ®Google Scholar
• Benschop R. J., Aviszus K., Zhang X., Manser T., Cambier J. C., Wysocki L. J.. Activation and anergy in bone marrow B cells of a novel immunoglobulin transgenic mouse that is both hapten specific and autoreactive. Immunity. 2001; 14:33–43.
   PubMedGoogle Scholar
• Tiegs S. L., Russell D. M., Nemazee D.. Receptor editing in self-reactive bone marrow B cells. J. Exper. Med.. 17719931009–1020.
   Google Scholar
• Li H., Jiang Y., Prak E. L., Radic M., Weigert M.. Editors and editing of anti-DNA receptors. Immunity. 2001; 15:947–957.
   PubMedGoogle Scholar
• Chen C., Li H., Tian Q., Beardall M., Xu Y., Casanova N., Weigert M.. Selection of anti-double-stranded DNA B cells in autoimmune MRL-lpr/lpr mice. J. Immunol.. 2006; 176:5183–5190.
   PubMedGoogle Scholar
• Kat I., Makdasi E., Fischel R., Eilat D.. B-cell anergy is maintained in anti-DNA transgenic NZB/NZW mice. Intern. Immunol.. 2010; 22:101–111.
   PubMedGoogle Scholar
• Fields M. L., Erikson J.. The regulation of lupus-associated autoantibodies: immunoglobulin transgenic models. Curr. Opin. Immunol.. 2003; 15:709–717.
   PubMed Web of Science ®Google Scholar
• Ota T., Ota M., Duong B. H., Gavin A. L., Nemazee D.. Liver-expressed Igκ superantigen induces tolerance of polyclonal B cells by clonal deletion not κto lambda receptor editing. J. Exper. Med.. 2011; 208:617–629.
   PubMedGoogle Scholar
• Kench J. A., Russell D. M., Nemazee D.. Efficient peripheral clonal elimination of B lymphocytes in MRL/lpr mice bearing autoantibody transgenes. J. Exper. Med.. 1998; 188:909–917.
   PubMedGoogle Scholar
• Hartley S. B., Crosbie J., Brink R., Kantor A. B., Basten A., Goodnow C. C.. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature. 1991; 353:765–769.
   PubMed Web of Science ®Google Scholar
• Rathmell J. C., Cooke M. P., Ho W. Y., Grein J., Townsend S. E., Davis M. M., Goodnow C. C.. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+T cells. Nature. 1995; 376:181–184.
   PubMed Web of Science ®Google Scholar
• Gauld S. B., Benschop R. J., Merrell K. T., Cambier J. C.. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nature Immunol.. 2005; 6:1160–1167.
   PubMed Web of Science ®Google Scholar
• Steeves M. A., Marion T. N.. Tolerance to DNA in (NZB x NZW)F1 mice that inherit an anti-DNA V(H) as a conventional micro H chain transgene but not as a V(H) knock-in transgene. J. Immunol.. 2004; 172:6568–6577.
   PubMedGoogle Scholar
• Sekiguchi D. R., Jainandunsing S. M., Fields M. L., Maldonado M. A., Madaio M. P., Erikson J., Weigert M., Eisenberg R. A.. Chronic graft-versus-host in Ig knockin transgenic mice abrogates B cell tolerance in anti-double-stranded DNA B cells. J. Immunol.. 2002; 168:4142–4153.
   PubMedGoogle Scholar
• Brard F., Shannon M., Prak E. L., Litwin S., Weigert M.. Somatic mutation and light chain rearrangement generate autoimmunity in anti-single-stranded DNA transgenic MRL/lpr mice. J. Exper. Med.. 1999; 190:691–704.
   PubMedGoogle Scholar
• Mandik-Nayak L., Seo S. J., Sokol C., Potts K. M., Bui A., Erikson J.. MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti-double-stranded DNA B cells. J. Exper. Med.. 1999; 189:1799–1814.
   PubMedGoogle Scholar
• Liu Y., Li L., Kumar K. R., Xie C., Lightfoot S., Zhou X. J., Kearney J. F., Weigert M., Mohan C.. Lupus susceptibility genes may breach tolerance to DNA by impairing receptor editing of nuclear antigen-reactive B cells. J. Immunol.. 2007; 179:1340–1352.
   PubMed Web of Science ®Google Scholar
• Mannoor K., Matejuk A., Xu Y., Beardall M., Chen C.. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. J. Immunol.. 2012; 188:3628–3638.
   PubMedGoogle Scholar
• Jiang C., Foley J., Clayton N., Kissling G., Jokinen M., Herbert R., Diaz M.. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J. Immunol.. 2007; 178:7422–7431.
   PubMed Web of Science ®Google Scholar
• Jiang C., Zhao M. L., Scearce R. M., Diaz M.. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis. Arthritis Rheumat.. 2011; 63:1086–1096.
   PubMed Web of Science ®Google Scholar
• Boes M., Schmidt T., Linkemann K., Beaudette B. C., Marshak-Rothstein A., Chen J.. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc. Natl. Acad. Sci. USA. 2000; 97:1184–1189.
   PubMed Web of Science ®Google Scholar
• Werwitzke S., Trick D., Kamino K., Matthias T., Kniesch K., Schlegelberger B., Schmidt R. E., Witte T.. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse. Arthritis Rheumat.. 2005; 52:3629–3638.
   PubMed Web of Science ®Google Scholar
• Liang Z., Chen C., Mohan C.. Molecular signatures of anti-nuclear antibodies: contributions of specific light chain residues and a novel New Zealand Black V kappa 1 germline gene. J. Immunol.. 2003; 171:3886–3894.
   PubMedGoogle Scholar
• Mietzner B., Tsuiji M., Scheid J., Velinzon K., Tiller T., Abraham K., Gonzalez J. B., Pascual V., Stichweh D., Wardemann H., Nussenzweig M. C.. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc. Natl. Acad. Sci. USA. 2008; 105:9727–9732.
   PubMed Web of Science ®Google Scholar
• Zhang J., Jacobi A. M., Wang T., Diamond B.. Pathogenic autoantibodies in systemic lupus erythematosus are derived from both self-reactive and non-self-reactive B cells. Mol. Med.. 2008; 14:675–681.
   PubMedGoogle Scholar
• Wellmann U., Letz M., Herrmann M., Angermuller S., Kalden J. R., Winkler T. H.. The evolution of human anti-double-stranded DNA autoantibodies. Proc. Natl. Acad. Sci. USA. 2005; 102:9258–9263.
   PubMed Web of Science ®Google Scholar
• Gilfillan S., Dierich A., Lemeur M., Benoist C., Mathis D.. Mice lacking TdT: mature animals with an immature lymphocyte repertoire. Science. 1993; 261:1175–1178.
   PubMed Web of Science ®Google Scholar
• Guo W., Smith D., Aviszus K., Detanico T., Heiser R. A., Wysocki L. J.. Somatic hypermutation as a generator of antinuclear antibodies in a murine model of systemic autoimmunity. J. Exp. Med.. 2010; 207:2225–2237.
   PubMed Web of Science ®Google Scholar
• Vyse T. J., Rozzo S. J., Drake C. G., Izui S., Kotzin B. L.. Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. J. Immunol.. 1997; 158:5566–5574.
   PubMed Web of Science ®Google Scholar
• Tsao B. P., Cantor R. M., Kalunian K. C., Chen C. J., Badsha H., Singh R., Wallace D. J., Kitridou R. C., Chen S. L., Shen N., Song Y. W., Isenberg D. A., Yu C. L., Hahn B. H., Rotter J. I.. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J. Clin. Invest.. 1997; 99:725–731.
   PubMed Web of Science ®Google Scholar
• Molano I. D., Redmond S., Sekine H., Zhang X. K., Reilly C., Hutchison F., Ruiz P., Gilkeson G. S.. Effect of genetic deficiency of terminal deoxynucleotidyl transferase on autoantibody production and renal disease in MRL/lpr mice. Clin. Immunol.. 2003; 107:186–197.
   PubMed Web of Science ®Google Scholar
• Feeney A. J., Lawson B. R., Kono D. H., Theofilopoulos A. N.. Terminal deoxynucleotidyl transferase deficiency decreases autoimmune disease in MRL-Fas(lpr) mice. J. Immunol.. 2001; 167:3486–3493.
   PubMedGoogle Scholar
• Shlomchik M. J., Madaio M. P., Ni D., Trounstein M., Huszar D.. The role of B cells in lpr/lpr-induced autoimmunity. J. Exper. Med.. 1994; 180:1295–1306.
   PubMed Web of Science ®Google Scholar
• Conde C., Weller S., Gilfillan S., Marcellin L., Martin T., Pasquali J. L.. Terminal deoxynucleotidyl transferase deficiency reduces the incidence of autoimmune nephritis in (New Zealand Black x New Zealand White)F1 mice. J. Immunol.. 1998; 161:7023–7030.
   PubMedGoogle Scholar
• Guth A. M., Zhang X., Smith D., Detanico T., Wysocki L. J.. Chromatin specificity of anti-double-stranded DNA antibodies and a role for Arg residues in the third complementarity-determining region of the heavy chain. J. Immunol.. 2003; 171:6260–6266.
   Google Scholar
• Krishnan M. R., Jou N. T., Marion T. N.. Correlation between the amino acid position of arginine in VH-CDR3 and specificity for native DNA among autoimmune antibodies. J. Immunol.. 1996; 157:2430–2439.
   PubMed Web of Science ®Google Scholar
• Li Z., Schettino E. W., Padlan E. A., Ikematsu H., Casali P.. Structure-function analysis of a lupus anti-DNA autoantibody: Central role of the heavy chain complementarity-determining region 3 Arg in binding of double- and single-stranded DNA. Euro. J. Immunol.. 2000; 30:2015–2026.
   PubMed Web of Science ®Google Scholar
• Smith D. S., Creadon G., Jena P. K., Portanova J. P., Kotzin B. L., Wysocki L. J.. Di- and trinucleotide target preferences of somatic mutagenesis in normal and autoreactive B cells. J. Immunol.. 1996; 156:2642–2652.
   PubMedGoogle Scholar
• Radic M. Z., Weigert M.. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Ann. Rev. Immunol.. 1994; 12:487–520.
   PubMed Web of Science ®Google Scholar
• Shlomchik M. J., Aucoin A. H., Pisetsky D. S., Weigert M. G.. Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse. Proc. Natl. Acad. Sci. USA. 1987; 84:9150–9154.
   PubMed Web of Science ®Google Scholar
• Shlomchik M., Mascelli M., Shan H., Radic M. Z., Pisetsky D., Marshak-Rothstein A., Weigert M.. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J. Exper. Med.. 1990; 171:265–292.
   PubMed Web of Science ®Google Scholar
• Connolly K., Roubinian J. R., Wofsy D.. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+T cells is required to suppress autoimmunity. J. Immunol.. 1992; 149:3083–3088.
   PubMedGoogle Scholar
• Peng S. L., Cappadona J., McNiff J. M., Madaio M. P., Owen M. J., Hayday A. C., Craft J.. Pathogenesis of autoimmunity in alphabeta T cell-deficient lupus-prone mice. Clin. Exper. Immunol.. 1998; 111:107–116.
   PubMed Web of Science ®Google Scholar
• Peng S. L., Madaio M. P., Hughes D. P., Crispe I. N., Owen M. J., Wen L., Hayday A. C., Craft J.. Murine lupus in the absence of alpha beta T cells. J. Immunol.. 1996; 156:4041–4049.
   PubMedGoogle Scholar
• Herlands R. A., Christensen S. R., Sweet R. A., Hershberg U., Shlomchik M. J.. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity. 2008; 29:249–260.
   PubMed Web of Science ®Google Scholar
• Sweet R. A., Ols M. L., Cullen J. L., Milam A. V., Yagita H., Shlomchik M. J.. Facultative role for T cells in extrafollicular Toll-like receptor-dependent autoreactive B-cell responses in vivo. Proc. Natl. Acad. Sci. USA. 2011; 108:7932–7937.
   PubMed Web of Science ®Google Scholar
• Mohan C., Adams S., Stanik V., Datta S. K.. Nucleosome: A major immunogen for pathogenic autoantibody-inducing T cells of lupus. J. Exper. Med.. 1993; 177:1367–1381.
   PubMed Web of Science ®Google Scholar
• Kaliyaperumal A., Mohan C., Wu W., Datta S. K.. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J. Exper. Med.. 1996; 183:2459–2469.
   PubMed Web of Science ®Google Scholar
• Shi Y., Kaliyaperumal A., Lu L., Southwood S., Sette A., Michaels M. A., Datta S. K.. Promiscuous presentation and recognition of nucleosomal autoepitopes in lupus: Role of autoimmune T cell receptor alpha chain. J. Exper. Med.. 1998; 187:367–378.
   PubMedGoogle Scholar
• Michaels M. A., Kang H. K., Kaliyaperumal A., Satyaraj E., Shi Y., Datta S. K.. A defect in deletion of nucleosome-specific autoimmune T cells in lupus-prone thymus: Role of thymic dendritic cells. J. Immunol.. 2005; 175:5857–5865.
   PubMedGoogle Scholar
• Singh R. R., Kumar V., Ebling F. M., Southwood S., Sette A., Sercarz E. E., Hahn B. H.. T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J. Exper. Med.. 1995; 181:2017–2027.
   PubMedGoogle Scholar
• Hahn B. H., Singh R. R., Tsao B. P., Ebling F. M.. Peptides from Vh regions of antibodies to DNA activate T cell help to upregulate autoantibody synthesis. Lupus. 1997; 6:330–332.
   PubMedGoogle Scholar
• Weiss S., Bogen B.. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc. Natl. Acad. Sci. USA. 1989; 86:282–286.
   PubMed Web of Science ®Google Scholar
• Bartnes K., Hannestad K.. Engagement of the B lymphocyte antigen receptor induces presentation of intrinsic immunoglobulin peptides on major histocompatibility complex class II molecules. Euro. J. Immunol.. 1997; 27:1124–1130.
   PubMedGoogle Scholar
• Snyder C. M., Zhang X., Wysocki L. J.. Negligible class II MHC presentation of B cell receptor-derived peptides by high density resting B cells. J. Immunol.. 2002; 168:3865–3873.
   PubMedGoogle Scholar
• Rudensky A. Y., Yurin V. L.. Immunoglobulin-specific T-B cell interaction. I. Presentation of self immunoglobulin determinants by B lymphocytes. Euro. J. Immunol.. 1989; 19:1677–1683.
   PubMedGoogle Scholar
• Holmoy T., Fredriksen A. B., Thompson K. M., Hestvik A. L., Bogen B., Vartdal F.. Cerebrospinal fluid T cell clones from patients with multiple sclerosis: recognition of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid B cells. Euro. J. Immunol.. 2005; 35:1786–1794.
   PubMedGoogle Scholar
• Hestvik A. L., Vartdal F., Fredriksen A. B., Thompson K. M., Kvale E. O., Skorstad G., Bogen B., Holmoy T.. T cells from multiple sclerosis patients recognize multiple epitopes on Self-IgG. Scand. J. Immunol.. 2007; 66:393–401.
   PubMedGoogle Scholar
• Detanico T., Heiser R. A., Aviszus K., Bonorino C., Wysocki L. J.. Self-tolerance checkpoints in CD4 T cells specific for a peptide derived from the B cell antigen receptor. J. Immunol.. 2011; 187:82–91.
   PubMedGoogle Scholar
• Eyerman M. C., Zhang X., Wysocki L. J.. T cell recognition and tolerance of antibody diversity. J. Immunol.. 1996; 157:1037–1046.
   PubMed Web of Science ®Google Scholar
• Guo W., Smith D., Guth A., Aviszus K., Wysocki L. J.. T cell tolerance to germline-encoded antibody sequences in a lupus-prone mouse. J. Immunol.. 2005; 175:2184–2190.
   PubMed Web of Science ®Google Scholar
• Bogen B., Jorgensen T., Hannestad K.. T helper cell recognition of idiotopes on lambda 2 light chains of M315 and T952: evidence for dependence on somatic mutations in the third hypervariable region. Euro. J. Immunol.. 1985; 15:278–281.
   PubMedGoogle Scholar
• Eyerman M. C., Wysocki L.. T cell recognition of somatically-generated Ab diversity. J. Immunol.. 1994; 152:1569–1577.
   PubMedGoogle Scholar
• Zhang X., Smith D. S., Guth A., Wysocki L. J.. A receptor presentation hypothesis for T cell help that recruits autoreactive B cells. J. Immunol.. 2001; 166:1562–1571.
   PubMedGoogle Scholar
• Munthe L. A., Os A., Zangani M., Bogen B.. MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. J. Immunol.. 2004; 172:7476–7484.
   PubMed Web of Science ®Google Scholar
• Snyder C. M., Aviszus K., Heiser R. A., Tonkin D. R., Guth A. M., Wysocki L. J.. Activation and tolerance in CD4(+) T cells reactive to an immunoglobulin variable region. J. Exper. Med.. 2004; 200:1–11.
   PubMedGoogle Scholar
• Vyse T. J., Kotzin B. L.. Genetic susceptibility to systemic lupus erythematosus. Ann. Rev. Immunol.. 1998; 16:261–292.
   PubMed Web of Science ®Google Scholar
• Wakeland E. K., Liu K., Graham R. R., Behrens T. W.. Delineating the genetic basis of systemic lupus erythematosus. Immunity. 2001; 15:397–408.
   PubMed Web of Science ®Google Scholar
• Fairhurst A. M., Wandstrat A. E., Wakeland E. K.. Systemic lupus erythematosus: Multiple immunological phenotypes in a complex genetic disease. Adv. Immunol.. 2006; 92:1–69.
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R., Brannan C. I., Copeland N. G., Jenkins N. A., Nagata S.. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992; 356:314–317.
   PubMed Web of Science ®Google Scholar
• Suzuki A., Kaisho T., Ohishi M., Tsukio-Yamaguchi M., Tsubata T., Koni P. A., Sasaki T., Mak T. W., Nakano T.. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J. Exp. Med.. 2003; 197:657–667.
   PubMed Web of Science ®Google Scholar
• O'Keefe T. L., Williams G. T., Batista F. D., Neuberger M. S.. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J. Exp. Med.. 1999; 189:1307–1313.
   PubMed Web of Science ®Google Scholar
• Burnet F. M.. 1972. Autoimmunity and Autoimmune Disease. Lancaster, UK: Medical and Technical Publishing Co. Ltd.
   Google Scholar
• Holzelova E., Vonarbourg C., Stolzenberg M. C., Arkwright P. D., Selz F., Prieur A. M., Blanche S., Bartunkova J., Vilmer E., Fischer A., Le Deist F., Rieux-Laucat F.. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N. Engl. J. Med.. 2004; 351:1409–1418.
   PubMed Web of Science ®Google Scholar
• Oliveira J. B., Bidere N., Niemela J. E., Zheng L., Sakai K., Nix C. P., Danner R. L., Barb J., Munson P. J., Puck J. M., Dale J., Straus S. E., Fleisher T. A., Lenardo M. J.. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc. Natl. Acad. Sci. USA. 2007; 104:8953–8958.
   PubMed Web of Science ®Google Scholar
• Takagi M., Shinoda K., Piao J., Mitsuiki N., Matsuda K., Muramatsu H., Doisaki S., Nagasawa M., Morio T., Kasahara Y., Koike K., Kojima S., Takao A., Mizutani S.. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood. 2011; 117:2887–2890.
   PubMed Web of Science ®Google Scholar
• Niemela J. E., Lu L., Fleisher T. A., Davis J., Caminha I., Natter M., Beer L. A., Dowdell K. C., Pittaluga S., Raffeld M., Rao V. K., Oliveira J. B.. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood. 2011; 117:2883–2886.
   PubMed Web of Science ®Google Scholar
• Hao Z., Hampel B., Yagita H., Rajewsky K.. T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis. J. Exp. Med.. 2004; 199:1355–1365.
   Google Scholar
• Hao Z., Duncan G. S., Seagal J., Su Y. W., Hong C., Haight J., Chen N. J., Elia A., Wakeham A., Li W. Y., Liepa J., Wood G. A., Casola S., Rajewsky K., Mak T. W.. Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. Immunity. 2008; 29:615–627.
   PubMedGoogle Scholar
• Stranges P. B., Watson J., Cooper C. J., Choisy-Rossi C. M., Stonebraker A. C., Beighton R. A., Hartig H., Sundberg J. P., Servick S., Kaufmann G., Fink P. J., Chervonsky A. V.. Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity. 2007; 26:629–641.
   PubMed Web of Science ®Google Scholar
• Fukuyama H., Adachi M., Suematsu S., Miwa K., Suda T., Yoshida N., Nagata S.. Requirement of Fas expression in B cells for tolerance induction. Eur. J. Immunol.. 2002; 32:223–230.
   PubMedGoogle Scholar
• Fukuyama H., Adachi M., Suematsu S., Miwa K., Suda T., Yoshida N., Nagata S.. Transgenic expression of Fas in T cells blocks lymphoproliferation but not autoimmune disease in MRL-lpr mice. J. Immunol.. 1998; 160:3805–3811.
   PubMed Web of Science ®Google Scholar
• Komano H., Ikegami Y., Yokoyama M., Suzuki R., Yonehara S., Yamasaki Y., Shinohara N.. Severe impairment of B cell function in lpr/lpr mice expressing transgenic Fas selectively on B cells. Int. Immunol.. 1999; 11:1035–1042.
   PubMedGoogle Scholar
• Cuda C. M., Agrawal H., Misharin A. V., Haines G. K.3rd, Hutcheson J., Weber E., Schoenfeldt J. A., Mohan C., Pope R. M., Perlman H.. Requirement of myeloid cell-specific Fas expression for prevention of systemic autoimmunity in mice. Arthritis Rheumat.. 2012; 64:808–820.
   PubMedGoogle Scholar
• Maher E. R., Yates J. R., Ferguson-Smith M. A.. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J. Med. Genet.. 1990; 27:311–314.
   PubMed Web of Science ®Google Scholar
• Chompret A., Brugieres L., Ronsin M., Gardes M., Dessarps-Freichey F., Abel A., Hua D., Ligot L., Dondon M. G., Bressac-de Paillerets B., Frebourg T., Lemerle J., Bonaiti-Pellie C., Feunteun J.. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br. J. Cancer. 2000; 82:1932–1937.
   PubMed Web of Science ®Google Scholar
• Knudson A. G.Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA. 1971; 68:820–823.
   PubMed Web of Science ®Google Scholar
• Eng C.. PTEN: one gene, many syndromes. Hum. Mutat.. 2003; 22:183–198.
   PubMed Web of Science ®Google Scholar
• Jachez B., Montecino-Rodriguez E., Fonteneau P., Loor F.. Partial expression of the lpr locus in the heterozygous state: presence of autoantibodies. Immunol.. 1988; 64:31–36.
   PubMed Web of Science ®Google Scholar
• Mastache E. F., Lindroth K., Fernandez C., Gonzalez-Fernandez A.. Somatic hypermutation of Ig genes is affected differently by failures in apoptosis caused by disruption of Fas (lpr mutation) or by overexpression of Bcl-2. Scand. J. Immunol.. 2006; 63:420–429.
   PubMedGoogle Scholar
• Takahashi Y., Ohta H., Takemori T.. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity. 2001; 14:181–192.
   PubMed Web of Science ®Google Scholar
• Di Cristofano A., Kotsi P., Peng Y. F., Cordon-Cardo C., Elkon K. B., Pandolfi P. P.. Impaired Fas response and autoimmunity in Pten+/ − mice. Science. 1999; 285:2122–2125.
   PubMedGoogle Scholar
• Shlomchik M. J., Marshak-Rothstein A., Wolfowicz C. B., Rothstein T. L., Weigert M. G.. The role of clonal selection and somatic mutation in autoimmunity. Nature. 1987; 328:805–811.
   PubMed Web of Science ®Google Scholar
• Blier P. R., Bothwell A.. A limited number of B cell lineages generates the heterogeneity of a secondary immune response. J. Immunol.. 1987; 139:3996–4006.
   PubMed Web of Science ®Google Scholar
• Pleasance E. D., Stephens P. J., O'Meara S., McBride D. J., Meynert A., Jones D., Lin M. L., Beare D., Lau K. W., Greenman C., Varela I., Nik-Zainal S., Davies H. R., Ordonez G. R., Mudie L. J., Latimer C., Edkins S., Stebbings L., Chen L., Jia M., Leroy C., Marshall J., Menzies A., Butler A., Teague J. W., Mangion J., Sun Y. A., McLaughlin S. F., Peckham H. E., Tsung E. F., Costa G. L., Lee C. C., Minna J. D., Gazdar A., Birney E., Rhodes M. D., McKernan K. J., Stratton M. R., Futreal P. A., Campbell P. J.. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010; 463:184–190.
   PubMed Web of Science ®Google Scholar
• Lee W., Jiang Z., Liu J., Haverty P. M., Guan Y., Stinson J., Yue P., Zhang Y., Pant K. P., Bhatt D., Ha C., Johnson S., Kennemer M. I., Mohan S., Nazarenko I., Watanabe C., Sparks A. B., Shames D. S., Gentleman R., de Sauvage F. J., Stern H., Pandita A., Ballinger D. G., Drmanac R., Modrusan Z., Seshagiri S., Zhang Z.. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010; 465:473–477.
   PubMed Web of Science ®Google Scholar
• Pleasance E. D., Cheetham R. K., Stephens P. J.. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455:1061–1068.
   PubMedGoogle Scholar
• Jones S., Zhang X., Parsons D. W., Lin J. C., Leary R. J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S. M., Fu B., Lin M. T., Calhoun E. S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D. R., Hidalgo M., Leach S. D., Klein A. P., Jaffee E. M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J. R., Kern S. E., Hruban R. H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V. E., Kinzler K. W.. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321:1801–1806.
   PubMed Web of Science ®Google Scholar
• Parsons D. W., Jones S., Zhang X., Lin J. C., Leary R. J., Angenendt P., Mankoo P., Carter H., Siu I. M., Gallia G. L., Olivi A., McLendon R., Rasheed B. A., Keir S., Nikolskaya T., Nikolsky Y., Busam D. A., Tekleab H., Diaz L. A.Jr, Hartigan J., Smith D. R., Strausberg R. L., Marie S. K., Shinjo S. M., Yan H., Riggins G. J., Bigner D. D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V. E., Kinzler K. W.. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321:1807–1812.
   PubMed Web of Science ®Google Scholar
• Stratton M. R., Campbell P. J., Futreal P. A.. The cancer genome. Nature. 2009; 458:719–724.
   PubMed Web of Science ®Google Scholar
• Hanahan D., Weinberg R. A.. The hallmarks of cancer. Cell. 2000; 100:57–70.
   PubMed Web of Science ®Google Scholar
• Cairns J.. Mutation selection and the natural history of cancer. Nature. 1975; 15.
   Google Scholar